112 related articles for article (PubMed ID: 16911520)
1. Interferon-alpha induces sensitization of cells to inhibition of protein synthesis by tumour necrosis factor-related apoptosis-inducing ligand.
Jeffrey IW; Elia A; Bornes S; Tilleray VJ; Gengatharan K; Clemens MJ
FEBS J; 2006 Aug; 273(16):3698-708. PubMed ID: 16911520
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of protein synthesis in apoptosis: differential requirements by the tumor necrosis factor alpha family and a DNA-damaging agent for caspases and the double-stranded RNA-dependent protein kinase.
Jeffrey IW; Bushell M; Tilleray VJ; Morley S; Clemens MJ
Cancer Res; 2002 Apr; 62(8):2272-80. PubMed ID: 11956083
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
Shi RX; Ong CN; Shen HM
Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950
[TBL] [Abstract][Full Text] [Related]
4. Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-alpha in human myeloma cells.
Gómez-Benito M; Balsas P; Bosque A; Anel A; Marzo I; Naval J
FEBS Lett; 2005 Nov; 579(27):6217-22. PubMed ID: 16246331
[TBL] [Abstract][Full Text] [Related]
5. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
Panichakul T; Intachote P; Wongkajorsilp A; Sripa B; Sirisinha S
Anticancer Res; 2006; 26(1A):259-65. PubMed ID: 16475706
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
7. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
Perego P; Ciusani E; Gatti L; Carenini N; Corna E; Zunino F
Biochem Pharmacol; 2006 Mar; 71(6):791-8. PubMed ID: 16438941
[TBL] [Abstract][Full Text] [Related]
8. Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins.
Fandy TE; Srivastava RK
Cancer Chemother Pharmacol; 2006 Oct; 58(4):471-7. PubMed ID: 16435155
[TBL] [Abstract][Full Text] [Related]
9. [Role of caspase-8 and DR5 in TRAIL-induced apoptosis of neuroblastoma cells].
Tong HX; Zhang JH; Ma L; Lu CW; Zhang JH
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Aug; 8(4):327-30. PubMed ID: 16923369
[TBL] [Abstract][Full Text] [Related]
10. Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis.
Deeb DD; Jiang H; Gao X; Divine G; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2005; 5(2):81-91. PubMed ID: 16471035
[TBL] [Abstract][Full Text] [Related]
11. 1-Methoxy-canthin-6-one induces c-Jun NH2-terminal kinase-dependent apoptosis and synergizes with tumor necrosis factor-related apoptosis-inducing ligand activity in human neoplastic cells of hematopoietic or endodermal origin.
Ammirante M; Di Giacomo R; De Martino L; Rosati A; Festa M; Gentilella A; Pascale MC; Belisario MA; Leone A; Turco MC; De Feo V
Cancer Res; 2006 Apr; 66(8):4385-93. PubMed ID: 16618764
[TBL] [Abstract][Full Text] [Related]
12. TRAIL-induced cleavage and inactivation of SPAK sensitizes cells to apoptosis.
Polek TC; Talpaz M; Spivak-Kroizman TR
Biochem Biophys Res Commun; 2006 Oct; 349(3):1016-24. PubMed ID: 16950202
[TBL] [Abstract][Full Text] [Related]
13. TRAIL-induced cytotoxicity in a melphalan-resistant rhabdomyosarcoma cell line via activation of caspase-2.
Klüttermann K; Banning U; Kachel M; Krause C; Körholz D; Mauz-Körholz C
Anticancer Res; 2006; 26(1A):351-6. PubMed ID: 16475717
[TBL] [Abstract][Full Text] [Related]
14. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics.
McManus DC; Lefebvre CA; Cherton-Horvat G; St-Jean M; Kandimalla ER; Agrawal S; Morris SJ; Durkin JP; Lacasse EC
Oncogene; 2004 Oct; 23(49):8105-17. PubMed ID: 15378029
[TBL] [Abstract][Full Text] [Related]
15. E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short).
Salon C; Eymin B; Micheau O; Chaperot L; Plumas J; Brambilla C; Brambilla E; Gazzeri S
Cell Death Differ; 2006 Feb; 13(2):260-72. PubMed ID: 16052233
[TBL] [Abstract][Full Text] [Related]
16. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
17. Enforced expression of a truncated form of Bax-alpha (tBax) driven by human telomerase reverse transcriptase (hTERT) promoter sensitizes tumor cells to chemotherapeutic agents or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Toyota H; Kondo S; Kyo S; Mizuguchi J
Anticancer Res; 2006; 26(1A):99-105. PubMed ID: 16475685
[TBL] [Abstract][Full Text] [Related]
18. Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators.
Cassatella MA; Huber V; Calzetti F; Margotto D; Tamassia N; Peri G; Mantovani A; Rivoltini L; Tecchio C
J Leukoc Biol; 2006 Jan; 79(1):123-32. PubMed ID: 16244105
[TBL] [Abstract][Full Text] [Related]
19. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
[TBL] [Abstract][Full Text] [Related]
20. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
